Journal article

Relevance of the Immunoglobulin V-H somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

Katherine I Lin, Constantine S Tam, Michael J Keating, William G Wierda, Susan O'Brien, Susan Lerner, Kevin R Coombes, Ellen Schlette, Alessandra Ferrajoli, Lynn L Barron, Thomas J Kipps, Laura Rassenti, Stefan Faderl, Hagop Kantarjian, Lynne V Abruzzo

BLOOD | AMER SOC HEMATOLOGY | Published : 2009

Abstract

Although immunoglobulin V(H) mutation status (IgV(H) MS) is prognostic in patients with chronic lymphocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its significance in the era of chemoimmunotherapy is not known. We determined the IgV(H) somatic mutation status (MS) in 177 patients enrolled in a phase 2 study of fludarabine, cyclophosphamide, and rituximab (FCR) and in 127 patients treated with subsequent chemoimmunotherapy protocols. IgV(H) MS did not impact significantly on the complete remission (CR) rate of patients receiving FCR or related regimens. However, CR duration was significantly shorter in patients with CLL that used unmutated IgV(H) th..

View full abstract